Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood
AR Smith, JE Wagner - British journal of haematology, 2009 - Wiley Online Library
Umbilical cord blood has rapidly become a valuable alternative stem cell source for
allogeneic haematopoietic stem cell transplantation. Extensive research over the last 20 …
allogeneic haematopoietic stem cell transplantation. Extensive research over the last 20 …
Oral graft-versus-host disease
MM Schubert, MEP Correa - Dental Clinics of North America, 2008 - Elsevier
Hematopoietic cell transplantation is used to treat malignancies, hematologic and immune
deficiency states, marrow failure syndromes, and autoimmune diseases. Graft-versus-host …
deficiency states, marrow failure syndromes, and autoimmune diseases. Graft-versus-host …
[HTML][HTML] Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation
NS Majhail, SH Farnia, PA Carpenter… - Biology of Blood and …, 2015 - Elsevier
Abstract Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are
performed in the United States annually. With advances in transplantation technology and …
performed in the United States annually. With advances in transplantation technology and …
Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia …
T Klingebiel, J Cornish, M Labopin… - Blood, The Journal …, 2010 - ashpublications.org
T cell–depleted haploidentical hematopoietic stem cell transplantation (haploHSCT) is an
option to treat children with very high-risk acute lymphoblastic leukemia (ALL) lacking an …
option to treat children with very high-risk acute lymphoblastic leukemia (ALL) lacking an …
Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)–rearranged acute …
G Mann, A Attarbaschi, M Schrappe… - Blood, The Journal …, 2010 - ashpublications.org
To define a role for hematopoietic stem cell transplantation (HSCT) in infants with acute
lymphoblastic leukemia and rearrangements of the mixed-lineage-leukemia gene (MLL+) …
lymphoblastic leukemia and rearrangements of the mixed-lineage-leukemia gene (MLL+) …
Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self
L Ruggeri, F Aversa, MF Martelli… - Immunological …, 2006 - Wiley Online Library
Although the optimal donor for allogeneic hematopoietic stem cell transplantation (HSCT) is
a human leukocyte antigen‐matched sibling, 75% of patients do not have a match, and …
a human leukocyte antigen‐matched sibling, 75% of patients do not have a match, and …
Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors
PJ Shaw, F Kan, K Woo Ahn… - Blood, The Journal …, 2010 - ashpublications.org
Although some trials have allowed matched or single human leukocyte antigen (HLA)–
mismatched related donors (mmRDs) along with HLA-matched sibling donors (MSDs) for …
mismatched related donors (mmRDs) along with HLA-matched sibling donors (MSDs) for …
Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952
S Malempati, PS Gaynon, H Sather, MK La… - Journal of Clinical …, 2007 - ascopubs.org
Purpose The event-free survival (EFS) of children with standard-risk acute lymphoblastic
leukemia (SR-ALL) is now more than 80%. However, prognosis after relapse continues to be …
leukemia (SR-ALL) is now more than 80%. However, prognosis after relapse continues to be …
Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
A Balduzzi, L Di Maio, D Silvestri… - British journal of …, 2014 - Wiley Online Library
Eighty‐two children and adolescents who underwent allogeneic transplantation for acute
lymphoblastic leukaemia in remission (period 2001–2011, median follow‐up 4· 9 years) had …
lymphoblastic leukaemia in remission (period 2001–2011, median follow‐up 4· 9 years) had …
[HTML][HTML] Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era
NS Majhail, P Chitphakdithai, B Logan, R King… - Biology of Blood and …, 2015 - Elsevier
Patients and physicians may defer unrelated donor hematopoietic cell transplantation (HCT)
as curative therapy because of the mortality risk associated with the procedure. Therefore, it …
as curative therapy because of the mortality risk associated with the procedure. Therefore, it …